Substrate inhibition of lysosomal hydrolases: α-Galactosidase A and β-glucocerebrosidase

Clinical Biochemistry

Volumn 44, Issue 10-11, 2011, Pages 941-943

  Kwapiszewski, Radoslaw ^a   Czartoryska, Barbara ^b   Ziolkowska, Karina ^a   Chudy, Michal ^a   Dybko, Artur ^a   Brzozka, Zbigniew ^a  

^a WARSAW UNIVERSITY OF TECHNOLOGY   (Poland)

^b INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

Galactosidase A and Glucocerebrosidase activity; Fabry disease; Gaucher disease; Substrate inhibition

Indexed keywords

ALPHA GALACTOSIDASE; GLUCOSYLCERAMIDASE; HYMECROMONE;

ARTICLE; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME SUBSTRATE; FABRY DISEASE; GAUCHER DISEASE; HUMAN; HUMAN CELL; INHIBITION KINETICS; LEUKEMIA CELL LINE; PRIORITY JOURNAL; SPECTROFLUOROMETRY; TEMPERATURE SENSITIVITY;

ALPHA-GALACTOSIDASE; BIOCATALYSIS; GLUCOSYLCERAMIDASE; HUMANS; HYMECROMONE; JURKAT CELLS; LYSOSOMES; SUBSTRATE SPECIFICITY; TEMPERATURE;

EID: 79958859745     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.04.018     Document Type: Article

References (15)

1. Pastores G.M. Lysosomal storage disorders: principles and practice 2009, World Scientific Publishing Company.
2. Ballabio A., Gieselman V. Lysosomal disorders: from storage to cellular damage. Biochim Biophys Acta 2009, 1793:684-696.
3. Meikle P.J., Grasby D.J., Dean C.J., Lang D.L., Bockamnn M., Whittle A.M., et al. Newborn screening for lysosomal storage disorders. Mol Genet Met 2006, 88:307-314.
4. de Duve C. The lysosome turns fifty. Nat Cell Biol 2005, 7:847-849.
5. de Fost M., Aerts J.M.F.G., Hollak C.E.M. Gaucher disease: from fundamental research to effective therapeutic interventions. Neth J Med 2003, 61:3-8.
6. Chamoles N.A., Blanco M., Gaggioli D. Fabry disease: enzymatic diagnosis in dried blood spots on filter paper. Clin Chim Acta 2001, 308:195-196.
7. Kitagawa T., Suzuki K., Ishige N., Ohsahi T., Kobayashi M., Eto Y., et al. Non-invasive high-risk screening for Fabry disease hemizygotes and heterozygotes. Pediatr Nephrol 2008, 23:1461-1471.
8. Lin Y., Lu P., Tang C., Mei Q., Sandig G., Rodrigues A.D., et al. Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. Drug Metab Dispos 2001, 29:368-374.
9. Copeland R.A. Enzymes: a practical introduction to structure, mechanism, and data analysis 2000, Wiley-VCH, Inc., New York.
10. Losman M.J. Beta-glucosidase activity as a diagnostic index of Gaucher's disease. S Afr Med J 1974, 48:1150-1152.
11. Daniels L.B., Glew R.H., Diven W.F., Lee R.E., Radin N.S. An improved fluorimetric leukocyte β-glucosidase assay for Gaucher's disease. Clin Chim Acta 1981, 115:369-375.
12. Bishop D.F., Desnick R.J. Affinity purification of β-galactosidase A from human spleen, placenta, and plasma with elimination of pyrogen contamination. J Biol Chem 1981, 256:1307-1316.
13. Daniels L.B., Glew R.H. β-Glucosidase assays in the diagnosis of Gaucher's disease. Clin Chem 1982, 28:569-577.
14. Desnick R.J., Allen KY K.Y., Desnick S.J., Raman M.K., Bernlohr R.W., Krivit W. Fabry's disease: enzymatic diagnosis of hemizygotes and heterozygotes. β-Galactosidase activities in plasma, serum, urine, and leukocytes. J Lab Clin Med 1973, 81:157-171.
15. Urban D.J., Zheng W., Goker-Alpan O., Jadhav A., LaMarca M.E., Inglese J., et al. Optimization and validation of two miniaturized glucocerebrosidase enzyme assays for high throughput screening. Comb Chem High T Scr 2008, 11:817-824.